Restoring the Body's Supply of an Essential Protein
DiaMedica Therapeutics is developing DM199, a recombinant protein replacement therapy intended to restore normal, healthy levels of a protein known as tissue kallikrein 1 (KLK1). KLK1 is a naturally-occurring protein believed to stimulate the production of nitric oxide, cGMP, prostaglandin and cAMP—factors that improve blood flow and reduce inflammation. DM199 has the potential to treat several acute and chronic diseases.